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Purpose: The efficacy of solvent—detergent-treated fibrin sealant (human [FSH]) for
controlling anastomotic bleeding from expanded polytetrafluoroethylene (ePTFE) patch
angioplasty during carotid endarterectomy was evaluated, and FSH was compared with
thrombin-soaked gelatin sponge (Gelfoam; TSG). 
Methods: The study was of a randomized, open-label, single-site, single-treatment, paral-
lel design that took place in a referral center with hospitalized patients. Forty-seven
adult patients (33 men, 14 women) underwent elective carotid endarterectomy. Patients
were randomized to receive either FSH (N = 24) or TSG (N = 23). FSH was obtained
as an investigational new drug. FSH was applied as a liquid by means of a dual-syringe
technique. Heparin anticoagulation, patch thickness, and suture type were standardized.
Two different needle sizes were used (CV-6, PT-13: N = 21 [FSH: N = 10, TSG: N =
11]; CV-6, PT-9: N = 26 [FSH: N = 14, TSG: N = 13]). The FSH or TSG was applied
to the ePTFE patch, and then blood flow was restored through the carotid artery.
Degree of anticoagulation was assessed by anti-factor Xa activity. The time from restora-
tion of carotid blood flow until achieving hemostasis was recorded. The blood loss from
patch suture hole bleeding was measured. Completion intraoperative duplex ultrasound
scanning was performed in all cases. Heparin was reversed with protamine sulfate. The
primary end point was successful hemostasis within 15 minutes of restoration of carotid
blood flow. The secondary end points were the amount of blood loss caused by suture
line bleeding and the time to achieve hemostasis.
Results: There was no difference in the number of patients with complete hemostasis at
15 minutes (TSG, 13 of 23; FSH, 12 of 24; P = .77). The measured blood loss was 99.0
± 119.9 (SD) mL for TSG, and 105.0 ± 107.9 mL for FSH (P = .86). The time to hemo-
stasis was the same for both groups (TSG, 16.5 ± 16.5 minutes; FSH, 16.6 ± 14.2 min-
utes; P = .97). Within both treatment groups, the use of larger needles (PT-13) was
associated with greater blood loss (FSH, 169.7 ± 124.2 mL; TSG, 172.7 ± 151.5 mL)
than was the use of smaller needles (PT-9; FSH, 58.8 ± 66.3 mL; TSG, 34.1 ± 25.6 mL;
P = .036, P = .001, respectively). There were no postoperative strokes or bleeding com-
plications in either group. No abnormalities were shown in either group by means of
completion carotid duplex ultrasound scanning.
Conclusion: FSH was equivalent, but not superior to, TSG in achieving hemostasis during
461
From the Department of Surgery, Division of Vascular Surgery,
University of Texas Southwestern Medical Center (Dr
Jackson), the Department of Surgery, Vascular Surgery Service,
Walter Reed Army Medical Center (Drs Gillespie, Goff, Fiala,
and O’Donnell and Ms Longenecker), the Division of
Medicine, Department of Hematology, Walter Reed Army
Institute of Research (Dr Alving), and Baxter Healthcare
Corporation, Hyland Division (Dr Gomperts and Mss Navalta
and Hestlow).
Supported by a grant from The Henry M. Jackson Foundation
(from Baxter Healthcare Corporation, Hyland Division, and
The American Red Cross).
Presented at the Twenty-third Annual Meeting of The Southern
Association for Vascular Surgery, Naples, Fla, Jan 27–30, 1999.
Reprint requests: Mark R. Jackson, MD, Department of Surgery,
Division of Vascular Surgery, University of Texas Southwestern
Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75235-
9157.
Copyright © 1999 by the Society for Vascular Surgery and
International Society for Cardiovascular Surgery, North
American Chapter.
0741-5214/99/$8.00 + 0 24/6/99681
Currently available topical hemostatic agents
(oxidized cellulose, purified gelatin, and bovine col-
lagen) serve as mechanical templates on which
thrombus forms and are limited in efficacy because
of their lack of any inherent coagulation mechanism.
Fibrin sealant, however, mimics the final step of the
coagulation cascade and has been used to promote
hemostasis in a variety of cardiac and vascular proce-
dures.1-3 Fibrin sealant is generally prepared as a
mixture of separate solutions of fibrinogen and
thrombin. 
Until the recent approval of a commercially pre-
pared fibrin sealant (Tisseel, Immuno AG, Vienna,
Austria) by the US Food and Drug Administration,
the clinical use of fibrin sealant, or “fibrin glue,” has
been restricted to cases in which significant bleeding
warrants exposure to pooled human cryoprecipitate
as the source of fibrinogen. Commercial prepara-
tions of fibrin sealant are treated with a variety of
virus inactivation methods that essentially eliminate
the risks of blood-borne diseases. An additional
advantage of commercial preparations is their fib-
rinogen concentration, which is higher than cryo-
precipitate based fibrin glue.4,5 Despite these ad-
vances, the hemostatic efficacy of commercially pre-
pared fibrin sealant compared with conventional
topical hemostatic agents when used in peripheral
vascular surgery has not been assessed in a random-
ized clinical trial. The hemostatic efficacy of a com-
mercially prepared, human fibrin sealant for control-
ling suture hole bleeding from expanded polytetra-
fluoroethylene (ePTFE) patch angioplasty during
carotid endarterectomy was studied.
METHODS
Study design. Forty-seven patients undergoing
elective carotid endarterectomy and ePTFE patch
angioplasty for atherosclerotic occlusive disease were
randomized to receive one of two topical hemostat-
ic agents for ePTFE patch suture hole bleeding: fib-
rin sealant (Human [FSH]) or thrombin-soaked
gelatin sponge (Gelfoam; TSG). The experimental
protocol and informed consent were approved by
the Institutional Review Board, and all subjects gave
informed consent. 
Patient selection. All patients undergoing elec-
tive carotid endarterectomy with ePTFE patch clo-
sure were eligible for the study. Conditions that were
cause for exclusion from the study included: redo
operations; patients requiring continuous postopera-
tive anticoagulation (eg, prosthetic heart valve);
patients with coagulopathy or uremia; patients under-
going primary closure of the carotid artery; and
patients requiring intraoperative shunting of the
carotid artery. Placement of a shunt was a criterion for
exclusion because the protocol required a 2-minute
period of annealing of the sealant before restoration
of carotid blood flow. This delay in carotid perfusion
was considered to be a safety concern in shunt-depen-
dent patients. 
Study materials. TSG (Gelfoam, Upjohn,
Kalamazoo, Mich) is an absorbable gelatin sponge
commonly used for topical hemostasis. The Gelfoam
was cut into 1.0 by 3.0 cm strips before use. Bovine
thrombin (1000 IU/mL, GenTrac, Middelton,
Wis) solution was applied to the wafers of Gelfoam.
FSH (Baxter Healthcare, Hyland Division, Glen-
dale, Calif, and the American Red Cross, Rockville,
Md) was obtained as an investigational new drug
(IND No. 4353). FSH is composed of a solution of
purified human fibrinogen (100 mg/mL) and a solu-
tion of purified human thrombin (300 U/mL) and
calcium chloride. The FSH was applied as a liquid by
means of a dual syringe technique with 3 mL of each
solution. Both components are made from plasma
donors with alanine aminotransferase levels less than
two times the upper limit of normal, and the plasmas
have tested negative for hepatitis B virus (HBV),
hepatitis C virus (HCV), and human immunodefi-
ciency virus (HIV). The components are also treated
with solvent/detergent suspension to inactivate
potential blood-borne, lipid-enveloped viruses (HBV,
HCV, HIV).
Expanded polytetrafluoroethylene patch and
suture material. Goretex (WL Gore, Flagstaff,
Ariz) cardiovascular patches of 0.04 mm thickness
were used for all carotid patch angioplasty closures.
Goretex sutures were used for the patch anastomo-
sis (CV-6, PT-13: N = 21 [FSH: N = 10, TSG: N =
11]; CV-6, PT-9: N = 26 [FSH: N = 14, TSG: N =
13]). Assignment to the two suture/needle size
groups was randomized.
Method of assigning patients to treatment
groups. Fifty-six patients consented to the study.
Forty-seven patients were randomized into two treat-
ment groups (FSH and TSG). Randomization oc-
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carotid endarterectomy performed with ePTFE patch angioplasty. Adhesion properties
of FSH to ePTFE are possibly different than those to native tissue and warrant addi-
tional investigation. (J Vasc Surg 1999;30:461-7.)
curred after completion of the ePTFE patch closure.
All nine withdrawals occurred before randomization.
Seven patients were withdrawn because a shunt was
needed. One patient was withdrawn because the artery
was closed primarily. One patient was withdrawn for
non—study-related reasons. The randomization pro-
cedure was block allocation, in which a block size of six
was used for the assignments into the two groups. The
choice of study group within a block was made accord-
ing to a random number table.6 The randomization
code was provided to the site through individually
sealed envelopes. 
Surgical and experimental procedure. All
carotid endarterectomies were performed with
local/regional anesthesia. All patients received aspirin
(325 mg orally) preoperatively. Before clamping of
the carotid artery, intravenous heparin was adminis-
tered (100 U/kg). After flushing and back-bleeding
of the arteries, administration of heparin-saline solu-
tion (10 U/mL) into the endarterectomy bed, and
closure of the patch, the treatment agent (FSH or
TSG) was applied to the patch so that all suture holes
were covered. Arterial flow was reestablished after a
2-minute annealing time to allow polymerization of
the FSH. After hemostasis was obtained, the carotid
artery was examined with intraoperative duplex ultra-
sound scanning. After technical adequacy was con-
firmed by means of ultrasound scanning, the heparin
was reversed with intravenous protamine sulfate (1
mg/100 units heparin).
Intraoperative duplex ultrasound scanning
protocol. Duplex ultrasound scanning was per-
formed with a dedicated intraoperative 10-MHZ
probe (Entos CL10-5 Intraoperative Scanhead, ATL
Ultrasound, Bothell, Wash). The examination proto-
col required inspection of the entire endarterectomy
bed, the proximal and distal end points, and the
clamp sites on the common, internal, and external
carotid arteries. B-mode was also used as a means of
inspecting all these sites. Patency of the external
carotid artery was also specifically assessed. Velocity
measurements were routinely recorded at the distal
end point and at any other site, at the discretion of the
attending vascular surgeon. The study was considered
abnormal when intralumenal thrombus was noted,
when intimal defects larger than 1 mm were noted, or
when distal end point velocities exceeded 140 cm/s
(peak systolic) or 40 cm/s (end diastolic).7
Study end points. There was one primary end
point: hemostasis within 15 minutes. When hemo-
stasis was not achieved after 15 minutes, it was con-
sidered a study failure. The amount of blood loss
and time to hemostasis were secondary end points.
Blood loss was measured by means of the corrected
weight of all blood-soaked surgical sponges applied
to the carotid patch angioplasty during the 15-
minute observation period. During this time, suc-
tion was not used to aspirate blood, and no irrigat-
ing fluids were used. The wound was blotted dry
immediately before the 15-minute period. Blood
loss from all other times during surgery, including
the flushing and back-bleeding of the arteries, was
not counted in this measurement.
Assessment of anticoagulation. Assessment of
anticoagulation was performed by means of mea-
surement of anti-Xa activity at the time of applica-
tion of the treatment agent and again 2 minutes
after reversal of anticoagulation with protamine.
Anti-Xa activity was measured with the Rotachrome
Heparin kit (American Bioproducts, Parsippany, NJ)
run on the STA Compact (American Bioproducts).
Data analysis and statistics. The determina-
tion of sample size was based on these premises: with
standard topical hemostatic agents such as TSG, the
failure rate of hemostasis at 15 minutes was expect-
ed to be about 50%. With FSH, this rate was expect-
ed to be about 20%. To show this difference with a
5% significance level (alpha) and a power of 0.80, 45
patients per group were required. 
Continuous variables are expressed as the mean ±
standard deviation, unless otherwise noted. The dif-
ference in hemostatic efficacy between FSH and TSG
were compared by means of the chi-square test for
two groups of discrete variables. Differences in blood
loss and time to hemostasis between groups were
compared by means of the Mann-Whitney U test.
Normally distributed quantitative data (eg, length of
carotid patch) were compared with unpaired t tests.
Because two different needle diameters were used
during the study (PT-13, PT-9) and there were two
treatment groups (FSH, TSG), the influence of nee-
dle size on hemostatic efficacy was assessed with the
Kruskal-Wallis test. Statistical analysis was performed
by means of the Statistical Package for the Social
Sciences (SPSS 7.5 for Windows, Chicago, Ill).
Significance was determined at the P ≤ .05 level.
RESULTS
Forty-seven patients undergoing elective carotid
endarterectomy were randomized to either FSH (N =
24) or TSG (N = 23). Randomization was halted after
an interim analysis was performed on 47 patients. The
mean age was 67.7 ± 6.6 years and was not different
between the two study groups (P = .72). There were
33 men and 14 women enrolled. Of the patients
receiving FSH (N = 24), 15 (62%) were men, and
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nine (38%) were women. Of the patients receiving
TSG (N = 23), 18 (78%) were men, and five (22%)
were women. Carotid endarterectomy was performed
for asymptomatic disease in 35 patients (74.5%) and
for symptomatic disease in 12 patients (25.5%).
Hemostasis was achieved within 15 minutes in
12 of 24 patients (50%) in the FSH group and in 12
of 23 patients (52.2%) of the TSG group (P = .882).
Similarly, no significant differences were observed
between groups in the two secondary end points,
measured blood loss and time to hemostasis (Table
I). Preoperative and postoperative hematocrit values
were similar in both groups (preoperative: FSH,
39.6 ± 3.1; TSG, 39.2 ± 3.7; P = .755; postopera-
tive: FSH, 32.0 ± 3.8; TSG, 32.5 ± 3.7; P = .680).
Because two different needle diameters were
used during the study, the effect of this variable on
blood loss and time to hemostasis was also analyzed
(Table II). More blood loss was recorded when
ePTFE patch angioplasties were closed with the larg-
er needle (PT-13) than with the smaller needle (PT-
9). No differences were observed, however, between
treatment groups when analyzed separately for nee-
dle diameter. Time to hemostasis was not signifi-
cantly different with either needle diameter.
Extra sutures were required in four cases (FSH,
3; TSG, 1). The measured blood loss in these four
cases was 82, 35, and 265 mL with FSH (mean, 127
mL) and 233 mL with TSG.
The mean length of the ePTFE carotid patches
was the same for both groups (FSH, 5.08 ± 0.97
cm; TSG, 5.31 ± 1.29 cm; P = .49). The degree of
anticoagulation was also similar in the two study
groups, both at the time of application of the topi-
cal agent and 2 minutes after protamine sulfate
administration. The anti-Xa activity at the time of
application of topical agent was 0.89 ± 0.28 U/mL
with FSH and 1.00 ± 0.19 with TSG (P = .132).
Two minutes after protamine, the anti-Xa activity
was 0.065 ± 0.10 with FSH and 0.15 ± 0.28 with
TSG (P = .161).
Although the adhesive properties of FSH to
ePTFE were not specifically assessed as part of this
study, there was a consistent observation among all
surgical investigators that the FSH did not adhere
well to the ePTFE patch material. Any degree of
persistent suture hole bleeding, even when it was
from only one or more suture holes, would cause the
polymerized “sheet” of FSH covering the patch to
separate from the ePTFE material, with resulting
persistent bleeding. 
There were no perioperative strokes, transient
ischemic attacks, or deaths in any of the 47 patients.
No bleeding complications occurred in either group.
The findings of all intraoperative completion duplex
scans were normal, with normal velocities and no
evidence of intralumenal thrombus. No serious
adverse events attributable to the study agent (FSH)
were observed. All patients were seen in follow-up
examinations within 45 days of surgery. No wound
complications were noted in either group.
DISCUSSION
The hemostatic efficacy of FSH was found to be
equivalent, but not superior to, TSG for controlling
suture hole bleeding from ePTFE patch angioplasty
during carotid endarterectomy. The hemostatic effi-
cacy, as measured by the primary and secondary end
points, was virtually identical in both groups.
Although the adhesive properties of FSH to ePTFE
were not specifically assessed as part of this study,
our subjective observation was that the fibrin sealant
tended to “float off” when there was persistent
suture hole bleeding. This suggests that fibrin
sealant, in the liquid form used in this study, has
poor adhesion characteristics when used with PTFE.
These adhesion characteristics potentially limit the
hemostatic efficacy of fibrin sealant as used in this
clinical situation. 
In a review of the material properties of fibrin
sealant, several studies have evaluated the adherence
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Table I. Secondary end points
Group Blood loss (mL ± SD) Time to hemostasis (min)
FSH 105.0 ± 107.8 17.8 ± 13.6
TSG 94.3 ± 121.2 19.5 ± 15.1
P = .551 P = .749
FSH, Fibrin sealant (human); TSG, thrombin-soaked gelatin
sponge.
Table II. Effect of needle size on bleeding
Time to hemo-
Group Treatment Needle size Blood loss stasis (min)
1 FSH PT-13 169.7 ± 124.2 14.8 ± 5.5
2 TSG PT-13 172.7 ± 151.5 18.8 ± 10.3
3 FSH PT-9 58.8 ± 66.3 19.9 ± 17.1
4 TSG PT-9 34.1 ± 25.6 19.9 ± 18.3
P = .001 P = .786
Needle size comparisons (blood loss): group 1 vs. Group 3, P =
.036; group 2 vs. group 4, P = .001.
Treatment group comparisons (blood loss): group 1 vs. group 2,
P = .762; group 3 vs. group 4, P = .207.
FSH, Fibrin sealant (human); TSG, thrombin-soaked gelatin sponge.
of fibrin and fibrin sealant to various adherends.8 In
one study, fibrin bonding was found to be greater in
collagen and skin grafts than to silicone sheeting
material.9 There are no studies that specifically eval-
uate the bonding properties of fibrin sealant to
ePTFE. Although fibrin sealant has been used to seal
Dacron and ePTFE vascular grafts, the ePTFE grafts
are generally pressure perfused with fibrin sealant ex
vivo.10
Milne and associates in Scotland evaluated the
hemostatic efficacy of fibrin sealant in 17 patients
undergoing carotid endarterectomy with ePTFE
patch angioplasty.2 The 17 patients were random-
ized to receive either fibrin sealant or no topical
agent. All nine patients in the control group were
subsequently treated with oxidized cellulose topical
agent. The fibrin sealant was provided by the
Scottish National Blood Transfusion Service and was
composed of heat-treated human fibrinogen con-
centrate and solvent–detergent-treated human
thrombin concentrate, both from pooled plasma.
These investigators found a significant reduction in
mean time to hemostasis with fibrin sealant versus
the control group (5.5 minutes vs. 19 minutes, P <
.005). No significant difference in blood loss was
observed, however. There are a number of differ-
ences between Milne’s study and ours that might
account for these results: (1) in the study by Milne
et al, only 5000 units of heparin were given, and
there was no laboratory assessment of anticoagula-
tion; (2) the needle diameter used in the two groups
was not specified; (3) the control group received no
initial treatment until bleeding occurred, at which
time oxidized cellulose was applied; (4) a slightly
thicker ePTFE patch was used (0.5 mm, vs. 0.4 mm
in our study); and (5) the fibrin sealant product was
slightly different in composition than that made by
Baxter Hyland.5 The fibrin sealant made by the
Scottish National Blood Transfusion Service has a
lower fibrinogen and thrombin concentration (40
mg/mL and 200 U/mL, respectively), a greater fac-
tor XIII concentration, and contains aprotinin com-
positional differences that would not be expected to
alter the immediate hemostatic properties of fibrin
sealant. Milne and colleagues did not describe the
quality of the adhesive bond between fibrin sealant
and the ePTFE patches. 
Rousou and colleagues investigated the hemo-
static efficacy of a commercially prepared fibrin
sealant in a randomized clinical trial of 333 patients
undergoing cardiac reoperation.1 Patients were ran-
domly assigned to receive either fibrin sealant or a
conventional topical hemostatic agent (gelatin
sponge, oxidized cellulose, microcrystalline colla-
gen, and bovine thrombin). Hemostatic efficacy, as
measured by means of complete hemostasis within 5
minutes, was observed in 92.6% of patients treated
with fibrin sealant and only 12.4% of those treated
with a conventional topical agent (P < .001). There
are two important differences in Rousou’s study and
ours. First, the sealant was applied to native tissue in
the mediastinum and not to a prosthetic surface as in
our study. Second, and perhaps most important,
their methodology allowed for the combined use of
fibrin sealant with a carrier of collagen felt (Helistat,
United States Surgical Corporation, Norwalk,
Conn). This type of combination of fibrin sealant
with a collagen backing material is commonly used
in Europe, where commercially prepared fibrin
sealant has been available for many years.11-13 We
have shown hemostatic efficacy of freeze-dried fibrin
sealant when applied with a backing material in an
animal model of femoral artery injury14 and an ani-
mal model of kidney injury with systemic anticoagu-
lation.15 The use of collagen or other backing mate-
rials with fibrin sealant for ePTFE suture hole bleed-
ing will require additional study to determine the
hemostatic efficacy of this combination. Although
the present study failed to demonstrate the superior-
ity of fibrin sealant over a collagen-based hemostatic
agent, Rousou’s study and our own preclinical data
would suggest that fibrin sealant might be preferable
to collagen-based hemostatic agent for treating
bleeding from tissue surfaces (as opposed to suture
hole bleeding from a prosthetic graft).
A potential safety concern that was addressed by
this study is whether intravascular thrombosis occurs
with extralumenal application of fibrin sealant to a
fresh arterial anastomosis. In an animal model of
carotid and femoral arterial bypass grafting with
ePTFE graft placement treated with fibrin sealant,
there was no evidence of fibrin sealant within the
lumen when the anastomoses were sectioned longi-
tudinally at the conclusion of the experiments.16 All
47 patients in our study were evaluated by means of
intraoperative duplex ultrasound scanning with a
dedicated, high-frequency intraoperative probe.
There was no evidence of intravascular thrombus in
any case. These results confirm the safety of applying
fibrin sealant to an arterial anastomosis.
An additional potential safety concern with the
use of any blood product is that of blood-borne
infection from hepatitis and HIV. The virus inactiva-
tion method used for the fibrin sealant studied here
is solvent/detergent treatment. This technique has
been shown to be an effective means of eliminating
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enveloped viruses (HBV, HCV, and HIV) from plas-
ma and plasma products.17 With a worldwide expe-
rience of 13 years and approximately 35 million
doses of a variety of solvent/detergent inactivated
products, there has not been a single documented
case of enveloped virus transmission.18 Although
hepatitis A is not lipid-enveloped and could poten-
tially be transmitted by the use of products inacti-
vated solely by the solvent/detergent method, evi-
dence indicates that hepatitis A is not typically trans-
mitted by blood products.18 Other methods of virus
inactivation, such as vapor heat, are effective in elim-
inating both enveloped and nonenveloped virus-
es.19,20 Tisseel (Immuno AG, Vienna, Austria), the
only US Food and Drug Administration-approved
fibrin sealant product, is treated with a two-step
vapor heat method.
In conclusion, FSH is equivalent, but not superi-
or, to TSG in achieving hemostasis from ePTFE
patch suture holes during carotid endarterectomy.
The hemostatic properties of fibrin sealant adminis-
tered as a combination of liquid fibrinogen and
thrombin are limited in the treatment of bleeding
from ePTFE suture holes. This limitation is possibly
caused by material properties and adhesive interac-
tions that warrant additional investigation. 
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Dr James M. Seeger (Gainesville, Fla). I would like to
congratulate Dr Jackson and his colleagues on a nice study.
In this prospective trial, 47 patients undergoing carotid
endarterectomy and polytetrafluoroethylene patch closure
were randomized to treatment with either fibrin sealant or
thrombin-soaked Gelfoam. Time to hemostasis, blood loss,
and activated factor Xa levels were then assessed.
Dr Jackson has shown that no differences were seen
in any of the outcome variables measured. In fact, the
only statistically significant observation in this study was
that there was more blood loss associated with use of larg-
er needles in the patch closure, compared with the small-
er needles. Apparently, the fibrin sealant appeared to
adhere poorly to the polytetrafluoroethylene patch, which
DISCUSSION
could have contributed to its lack of efficacy, although
this was not objectively assessed.
This well-done study does demonstrate the safety of
this fibrin sealant when used during carotid endarterecto-
my, but has failed to confirm its efficacy. Previous studies of
the use of fibrin sealant in cardiac procedures have shown
value, especially when the fibrin sealant was used on medi-
astinal tissue with a collagen-backing material. Potential
explanations for the lack of efficacy of the fibrin sealant in
this study, compared with previous observations made dur-
ing cardiac surgery, include the relatively limited amount of
bleeding that occurs from the carotid suture line after patch
closure in most patients and the limited adherence of the
fibrin sealant to the polytetrafluoroethylene patch.
I have several questions. Although the fibrin sealant is
not superior to thrombin-soaked Gelfoam when used rou-
tinely, could it potentially be of value in the occasional
patient who has “excessive” bleeding? Furthermore, is the
fibrin sealant useful after bleeding has begun?
Second, most persistent bleeding in my carotid
endarterectomies is not from the suture line, but from the
surrounding tissue. Would efficacy be shown if the fibrin
sealant were also used on the surrounding native tissue,
particularly at sites of persistent bleeding?
Third, what is the cost of this material, and can it be
made cost effective if it is shown to be efficacious? How
much time in the operating room must be saved to offset
the cost of the fibrin sealant?
Finally, is there a way to improve the adherence of the
sealant to the hydrophobic polytetrafluoroethylene mater-
ial, which limits adherence of all proteins, or is this
approach of limited value in limiting bleeding when poly-
tetrafluoroethylene material is used?
Again, I commend the authors on a well-done study.
Thank you.
Dr Mark R. Jackson. Thank you, Dr Seeger, for your
comments and remarks. About your first question regard-
ing the possible value of fibrin sealant in the occasional
patient with excessive bleeding, I think there is a potential
role, although this has yet to be demonstrated for most
surgical bleeding. As you pointed out, I think that fibrin
sealant is more likely to have a benefit in those patients in
whom the bleeding is from surrounding tissue. Perhaps
fibrin sealant might be of greater benefit in controlling
bleeding from the retroperitoneum during elective aortic
surgery, when there often is a continued oozing from the
retroperitoneum that doesn’t seem to respond well to
tamponade with surgical sponges or other topical hemo-
static agents.
Given the high cost and current delivery systems that
allow only a relatively small wound to be covered, it will
be difficult to demonstrate cost effectiveness. However,
other application devices are being developed that spray a
thin layer of fibrin sealant over a broader surface area. For
now, spray tip nozzles that attach to the syringe system are
available and would be the preferred device to apply fibrin
sealant for most surgical bleeding encountered during vas-
cular surgery.
As far as improving the adherence of fibrin sealant to
polytetrafluoroethylene, I am not aware of a solution to
this problem. Application of fibrin sealant with collagen-
felt backing material might partially address this problem.
There are other sealant and hemostasis products in devel-
opment that are based on collagen that might be more
suitable for use with polytetrafluoroethylene suture hole
bleeding, but this remains to be demonstrated.
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